Клинико-экономическая оценка терапии острых респираторных заболеваний у детей раннего возраста
Коровина Нина Алексеевна, Е М Овсянникова · CyberLeninK (CyberLeninka) · 2005
A clinical-economic evaluation of the use of fenspiride for treatment of ARD in infants was made in an open randomized comparative study. The observation involved 81 patient aged from 6 to 18 months. The basic group (fenspiride and symptomatic therapy) comprised 41 infant, the reference group (only symptomatic therapy) 40 infants. All patients in the groups were compatible by sex, age, and the clinical picture of the disease. The results of the study showed that the infants from the reference group had more persistent catarrhal symptoms, more often required antibacterial drugs, and stayed in hospital longer as compared with the patients of the basic group. The total cost of treatment of patients who received fenspiride amounted to 4240 rubles, of the reference group patients to 5450 rubles. Therefore, the study demonstrated that inclusion of fenspiride into ARD therapy in first-years infants is cost-efficient and increases the quality of medical aid.
Cited by 0 works.